What Is Your Skin Cancer IQ?

Publication
Article
OncologyONCOLOGY Vol 21 No 6
Volume 21
Issue 6

May is National Skin Cancer Awareness MonthWhat Is Your Skin Cancer IQ?Identifying BCC, SCC, and melanoma

 
Basal Cell Carcinoma (BCC)
Squamous Cell Carcinoma (SCC)
Melanoma

Appearance

Small, shiny bumps or nodules that are red, pink, or white; persistent, nonhealing sore; reddish flat patch; or a scar-like white or yellowish area
Red, scaly patches or bumps
Asymmetrical, mottled patches with notched or blurred borders, typically in tan, brown, or black
Size
Takes many years or months to reach a half-inch
Can reach up to three-quarters of an inch to an inch
Usually greater than 6 mm
Location
Head, neck, hands, and occasionally on the trunk of the body
Face, ears, neck, lips, and back of the hands
Can occur anywhere on the body, most frequently on the upper back or legs, as well as the head and neck
Progression
Grows slowly and may bleed, crust over, then the cycle repeats
Can develop into large masses
Can appear without warning, or may begin in or near a mole or other dark spot on the skin
Potential for metastasis
Rare, but can grow into nearby areas and may invade bone and vital structures, such as the eye
Can metastasize, and may be fatal if not treated
Can metastasize, and is deadly if not treated
Prevalence
BCC accounts for 80% of all skin cancers (more than 800,000 new cases each year).
SCC accounts for 16% of all skin cancers (approximately 250,000 new cases each year). About 2,500 deaths from SCC are expected during 2007.
Melanoma accounts for 4% of all skin cancers (approximately 59,940 new cases each year). More than 8,110 melanoma deaths are expected during 2007.

Adapted, with permission, from the American Academy of Dermatology’s “Actinic Keratoses and Skin Cancer,” available at http://www.aad.org/public/News/DermInfo/DInfoSkinCancerUpdates.htm.

Recent Videos
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.